X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-07 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale+OE | $77.84 | -18,700 | 212,523 | -8% | -$1,455,613 | |||||
| D | 2026-01-07 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale+OE | $40.20 | -25,156 | 0 | -100% | -$1,011,299 | |||||
| M | 2026-01-07 | ABOS | Acumen Pharmaceuticals, Inc. | Doherty James J. | Pres, CDO | S - Sale | $1.85 | -8,167 | 54,033 | -13% | -$15,148 | |||||
2026-01-07 | ABOS | Acumen Pharmaceuticals, Inc. | Schacterle Amy | Chief Regulatory Officer | S - Sale | $1.98 | -1,097 | 7,703 | -12% | -$2,176 | ||||||
| D | 2026-01-07 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | COO | S - Sale+OE | $100.56 | -75,000 | 141,053 | -35% | -$7,542,023 | |||||
| D | 2026-01-07 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale+OE | $98.00 | -10,000 | 108,065 | -8% | -$980,000 | |||||
| D | 2026-01-07 | VCEL | Vericel Corp | Halpin Michael | COO | S - Sale+OE | $40.48 | -10,000 | 16,080 | -38% | -$404,800 | |||||
2026-01-07 | GLUE | Monte Rosa Therapeutics, Inc. | Warmuth Markus | Pres, CEO | S - Sale | $23.49 | -5,466 | 618,937 | -1% | -$128,373 | ||||||
2026-01-07 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $26.53 | -1,203 | 199,611 | -1% | -$31,914 | ||||||
2026-01-06 | ADPT | Adaptive Biotechnologies Corp | Robins Harlan S | Chief Scientific Officer | S - Sale | $16.44 | -10,000 | 1,222,312 | -1% | -$164,400 | ||||||
| M | 2026-01-06 | DVLT | Datavault Ai Inc. | Scilex Holding Co | 10% | S - Sale | $1.24 | -14,713,490 | 229,731,770 | -6% | -$18,176,455 | |||||
| D | 2026-01-06 | CRSP | Crispr Therapeutics AG | Prasad Raju | CFO | S - Sale+OE | $60.16 | -29,700 | 6,767 | -81% | -$1,786,636 | |||||
2026-01-06 | SRZN | Surrozen, Inc./De | Column Group III Gp, LP | 10% | P - Purchase | $19.89 | +15,100 | 2,211,277 | +1% | +$300,297 | ||||||
2026-01-06 | SRZN | Surrozen, Inc./De | Kutzkey Tim | Dir, 10% | P - Purchase | $19.89 | +15,100 | 2,211,277 | +1% | +$300,297 | ||||||
2026-01-06 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $4.36 | -220,000 | 6,649,863 | -3% | -$959,200 | ||||||
| DM | 2026-01-06 | MAZE | Maze Therapeutics, Inc. | Sohn Catherine A. | Dir | S - Sale+OE | $39.07 | -29,413 | 0 | -100% | -$1,149,054 | |||||
2026-01-06 | DNLI | Denali Therapeutics Inc. | Watts Ryan J. | Pres, CEO | S - Sale | $16.50 | -35,198 | 2,449,437 | -1% | -$580,767 | ||||||
2026-01-06 | DNLI | Denali Therapeutics Inc. | Schuth Alexander O. | COFO, Secretary | S - Sale | $16.50 | -17,218 | 806,577 | -2% | -$284,097 | ||||||
| M | 2026-01-05 | ABOS | Acumen Pharmaceuticals, Inc. | Zuga Matt | CFO, Chief Business Officer | S - Sale | $1.97 | -14,905 | 216,839 | -6% | -$29,436 | |||||
| M | 2026-01-05 | ABOS | Acumen Pharmaceuticals, Inc. | Siemers Eric | Chief Medical Officer | S - Sale | $1.96 | -10,834 | 159,464 | -6% | -$21,277 | |||||
| M | 2026-01-05 | ABOS | Acumen Pharmaceuticals, Inc. | Oconnell Daniel Joseph | CEO | S - Sale | $1.98 | -47,506 | 619,982 | -7% | -$94,176 | |||||
| M | 2026-01-05 | ABOS | Acumen Pharmaceuticals, Inc. | Meisner Derek M | GC, Corp Sec | S - Sale | $1.98 | -26,668 | 134,459 | -17% | -$52,690 | |||||
| M | 2026-01-05 | ABOS | Acumen Pharmaceuticals, Inc. | Barton Russell | COO | S - Sale | $1.97 | -9,318 | 126,799 | -7% | -$18,325 | |||||
| AD | 2025-12-22 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $17.50 | -4,394 | 318,478 | -1% | -$76,895 | |||||
2026-01-05 | ADPT | Adaptive Biotechnologies Corp | Robins Chad M | CEO, COB | S - Sale | $15.59 | -124,998 | 2,584,243 | -5% | -$1,948,719 | ||||||
| M | 2017-03-31 | CDTX | Cidara Therapeutics, Inc. | Stein Jeffrey | Pres, CEO | P - Purchase | $79.55 | +4,262 | 75,640 | +6% | +$339,040 | |||||
| M | 2026-01-05 | PMCB | Pharmacyte Biotech, Inc. | Silverman Joshua | CEO, Pres | P - Purchase | $0.80 | +100,000 | 466,250 | +27% | +$80,476 | |||||
| M | 2026-01-05 | PMCB | Pharmacyte Biotech, Inc. | Schechter Jonathan | Dir | P - Purchase | $0.80 | +60,000 | 192,500 | +45% | +$48,232 | |||||
| D | 2026-01-05 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | Dir | S - Sale+OE | $4.25 | -40,000 | 913,839 | -4% | -$170,000 | |||||
2026-01-06 | RLAY | Relay Therapeutics, Inc. | Patel Sanjiv | Pres, CEO | S - Sale | $7.82 | -43,168 | 1,547,944 | -3% | -$337,574 | ||||||
| D | 2026-01-05 | SRZN | Surrozen, Inc./De | Li Yang | Exec. VP, Research | S - Sale+OE | $19.87 | -1,118 | 16,793 | -6% | -$22,209 | |||||
| D | 2026-01-05 | SRZN | Surrozen, Inc./De | Williams Charles O | COO | S - Sale+OE | $19.87 | -1,566 | 12,982 | -11% | -$31,109 | |||||
| DM | 2026-01-02 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | CFO | S - Sale+OE | $76.14 | -8,000 | 185,371 | -4% | -$609,146 | |||||
| D | 2026-01-02 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $16.08 | -3,125 | 318,478 | -1% | -$50,250 | |||||
2026-01-05 | HALO | Halozyme Therapeutics, Inc. | Connaughton Bernadette | Dir | S - Sale | $70.25 | -2,000 | 40,123 | -5% | -$140,500 | ||||||
| D | 2026-01-05 | SLDB | Solid Biosciences Inc. | Ganot Ilan | Dir | S - Sale+OE | $5.43 | -1,053 | 132,085 | -1% | -$5,718 | |||||
| DM | 2026-01-02 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale+OE | $40.39 | -4,844 | 0 | -100% | -$195,668 | |||||
| D | 2026-01-02 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Finance | S - Sale+OE | $39.15 | -5,000 | 12,965 | -28% | -$195,754 | |||||
2026-01-02 | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | S - Sale | $80.67 | -15,565 | 23,393 | -40% | -$1,255,684 | ||||||
| D | 2026-01-02 | ATHA | Athira Pharma, Inc. | San Martin Javier | CHIEF MEDICAL OFFICER | S - Sale+OE | $6.88 | -1,644 | 10,189 | -14% | -$11,311 | |||||
| D | 2026-01-02 | ATHA | Athira Pharma, Inc. | Litton Mark James | Pres, CEO | S - Sale+OE | $6.88 | -2,586 | 42,796 | -6% | -$17,792 | |||||
| D | 2026-01-02 | ATHA | Athira Pharma, Inc. | Renninger Robert | CFO | S - Sale+OE | $6.88 | -297 | 12,857 | -2% | -$2,043 | |||||
| D | 2026-01-02 | ATHA | Athira Pharma, Inc. | Church Kevin | Chief Scientific Officer | S - Sale+OE | $6.88 | -876 | 20,681 | -4% | -$6,027 | |||||
| D | 2026-01-02 | ATHA | Athira Pharma, Inc. | Worthington Mark | GC, CCO | S - Sale+OE | $6.88 | -876 | 13,978 | -6% | -$6,027 | |||||
2025-12-31 | BEAM | Beam Therapeutics Inc. | Emany Sravan Kumar | CFO | S - Sale | $27.10 | -6,294 | 73,706 | -8% | -$170,567 | ||||||
2025-12-31 | BEAM | Beam Therapeutics Inc. | Bellon Christine | GC | S - Sale | $27.10 | -1,254 | 115,667 | -1% | -$33,983 | ||||||
| D | 2026-01-05 | GLUE | Monte Rosa Therapeutics, Inc. | Nickson Philip | Chief Business, Legal Officer | S - Sale+OE | $15.17 | -3,155 | 60,845 | -5% | -$47,861 | |||||
| D | 2026-01-05 | GLUE | Monte Rosa Therapeutics, Inc. | Champoux Jennifer | COO | S - Sale+OE | $15.17 | -2,629 | 62,371 | -4% | -$39,882 | |||||
| D | 2026-01-02 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale+OE | $7.60 | -10,312 | 88,020 | -10% | -$78,371 | |||||
2026-01-05 | GLUE | Monte Rosa Therapeutics, Inc. | Dunn Edmund | Principal Accounting Officer | S - Sale | $15.17 | -1,039 | 22,693 | -4% | -$15,762 | ||||||
| D | 2026-01-05 | GLUE | Monte Rosa Therapeutics, Inc. | Warmuth Markus | Pres, CEO | S - Sale+OE | $15.17 | -10,135 | 624,403 | -2% | -$153,748 | |||||
| D | 2026-01-05 | GLUE | Monte Rosa Therapeutics, Inc. | Janku Filip | Chief Medical Officer | S - Sale+OE | $15.17 | -3,155 | 75,026 | -4% | -$47,861 | |||||
| D | 2026-01-05 | GLUE | Monte Rosa Therapeutics, Inc. | Townson Sharon | Chief Scientific Officer | S - Sale+OE | $15.17 | -3,155 | 67,845 | -4% | -$47,861 | |||||
2026-01-02 | VIR | Vir Biotechnology, Inc. | Sato Vicki L | Dir | S - Sale | $5.93 | -22,000 | 1,166,391 | -2% | -$130,383 | ||||||
2025-12-31 | PCVX | Vaxcyte, Inc. | Dhaliwal Harpreet S. | Chief Technical Ops Officer | S - Sale | $46.69 | -9,743 | 23,928 | -29% | -$454,891 | ||||||
| D | 2025-12-31 | KYMR | Kymera Therapeutics, Inc. | Mainolfi Nello | CEO | S - Sale+OE | $78.06 | -30,000 | 663,077 | -4% | -$2,341,939 | |||||
| DM | 2025-12-29 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | CSBO | S - Sale+OE | $40.56 | -72,500 | 10,503 | -87% | -$2,940,799 | |||||
| D | 2025-12-29 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale+OE | $40.56 | -45,000 | 0 | -100% | -$1,825,355 | |||||
| DM | 2025-12-29 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Finance | S - Sale+OE | $40.41 | -15,000 | 12,965 | -54% | -$606,173 | |||||
| AM | 2025-12-26 | DVLT | Datavault Ai Inc. | Scilex Holding Co | 10% | S - Sale | $0.62 | -20,657,300 | 244,445,260 | -8% | -$12,771,580 | |||||
| M | 2025-12-26 | SCLX | Scilex Holding Co | Scilex Holding Co | 10% | S - Sale | $0.62 | -20,657,300 | 244,445,260 | -8% | -$12,771,580 | |||||
2025-12-29 | RXRX | Recursion Pharmaceuticals, Inc. | Taylor Ben R | CFO | S - Sale | $4.18 | -21,383 | 761,550 | -3% | -$89,381 | ||||||
2025-12-24 | TARS | Tarsus Pharmaceuticals, Inc. | Azamian Bobak R. | Pres, CEO, Board Chair | S - Sale | $82.51 | -6,000 | 859,741 | -1% | -$495,089 | ||||||
2025-12-29 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $124.83 | -10,000 | 566,698 | -2% | -$1,248,272 | ||||||
2025-12-29 | ENTX | Entera Bio Ltd. | Toledano Miranda Jayne | CEO | P - Purchase | $1.81 | +11,000 | 426,575 | +3% | +$19,912 | ||||||
| D | 2025-12-22 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $17.50 | -4,394 | 318,478 | -1% | -$76,895 | |||||
2025-12-23 | PCVX | Vaxcyte, Inc. | Cowan Elvia | SVP, Finance | S - Sale | $47.92 | -11,623 | 13,534 | -46% | -$556,972 | ||||||
2025-12-26 | QNCX | Quince Therapeutics, Inc. | Benatti Luca | Dir | S - Sale | $3.47 | -50,000 | 39,179 | -56% | -$173,500 | ||||||
| D | 2025-12-22 | RXRX | Recursion Pharmaceuticals, Inc. | Khan Najat | Chief R, D Commercial Officer | S - Sale+OE | $4.41 | -124,403 | 611,135 | -17% | -$548,592 | |||||
2025-12-23 | CGEM | Cullinan Therapeutics, Inc. | Ahmed Nadim | Pres, CEO | S - Sale | $10.01 | -9,922 | 420,699 | -2% | -$99,319 | ||||||
2025-12-22 | IPSC | Century Therapeutics, Inc. | Cowan Chad | Chief Scientific Officer | P - Purchase | $0.85 | +58,060 | 1,055,784 | +6% | +$49,252 | ||||||
2025-12-24 | IMA | Imagenebio, Inc. | Slattery Joseph P | Dir | P - Purchase | $5.99 | +16,000 | 16,000 | New | +$95,840 | ||||||
2025-12-24 | FENC | Fennec Pharmaceuticals Inc. | Southpoint Capital Advisors LP | 10% | S - Sale | $7.50 | -1,000,000 | 2,744,741 | -27% | -$7,500,000 | ||||||
| D | 2025-12-20 | FDMT | 4D Molecular Therapeutics, Inc. | Gupta Ashoo | VP, Finance, Controller | S - Sale+OE | $8.68 | -389 | 46,359 | -1% | -$3,377 | |||||
2025-12-19 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | CFO | S - Sale | $80.00 | -1,500 | 193,371 | -1% | -$120,000 | ||||||
| M | 2025-12-19 | TCRX | Tscan Therapeutics, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $0.90 | +161,801 | 15,956,564 | +1% | +$145,526 | |||||
2025-12-22 | CRSP | Crispr Therapeutics AG | Prasad Raju | CFO | S - Sale | $55.95 | -10,000 | 6,767 | -60% | -$559,549 | ||||||
2025-12-22 | BCRX | Biocryst Pharmaceuticals Inc | Barnes Alane P | GC | S - Sale | $7.65 | -21,773 | 398,751 | -5% | -$166,563 | ||||||
2025-12-22 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $34.56 | -273 | 166,639 | 0% | -$9,434 | ||||||
2025-12-22 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $34.56 | -324 | 144,680 | 0% | -$11,196 | ||||||
| D | 2025-12-22 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $34.56 | -1,605 | 874,313 | 0% | -$55,462 | |||||
2025-12-19 | PLX | Protalix Biotherapeutics, Inc. | Bashan Dror | Pres, CEO | P - Purchase | $1.81 | +56,000 | 2,532,934 | +2% | +$101,360 | ||||||
2025-12-19 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale | $10.01 | -1,345 | 132,635 | -1% | -$13,463 | ||||||
2025-12-18 | KYTX | Kyverna Therapeutics, Inc. | Seidenberg Beth C | Dir | P - Purchase | $7.50 | +133,333 | 4,673,891 | +3% | +$999,998 | ||||||
2025-12-18 | KYTX | Kyverna Therapeutics, Inc. | Westlake Biopartners Opportunity Fund I, L.P. | 10% | P - Purchase | $7.50 | +133,333 | 4,657,257 | +3% | +$999,998 | ||||||
| D | 2025-11-01 | HALO | Halozyme Therapeutics, Inc. | Caudill Cortney | SVP, COO | S - Sale+OE | $65.19 | -4,263 | 12,737 | -25% | -$277,905 | |||||
| D | 2025-12-19 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $4.50 | -40,000 | 913,839 | -4% | -$180,000 | |||||
2025-12-18 | CGEM | Cullinan Therapeutics, Inc. | Sumer Jacquelyn L | GC | S - Sale | $9.67 | -3,480 | 135,432 | -3% | -$33,652 | ||||||
2025-12-18 | CGEM | Cullinan Therapeutics, Inc. | Jones Jeffrey Alan | Chief Medical Officer | S - Sale | $9.67 | -4,632 | 169,532 | -3% | -$44,791 | ||||||
2025-12-18 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale | $9.67 | -2,898 | 133,980 | -2% | -$28,024 | ||||||
2025-12-17 | ELUT | Elutia Inc. | Rakin Kevin | Dir, 10% | P - Purchase | $0.52 | +50,000 | 5,155,098 | +1% | +$25,995 | ||||||
| D | 2025-12-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $10.90 | -1,635 | 3,594 | -31% | -$17,822 | |||||
2025-12-18 | KOD | Kodiak Sciences Inc. | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | $23.00 | +2,608,696 | 18,358,772 | +17% | +$60,000,008 | ||||||
2025-12-18 | IMVT | Immunovant, Inc. | Van Tuyl Christopher | GC | S - Sale | $26.91 | -10,813 | 149,930 | -7% | -$290,943 | ||||||
| M | 2025-12-17 | DBVT | Dbv Technologies S.A. | Epic Bpifrance | Member of 10% owner group | S - Sale | $4.60 | -3,369,093 | 7,529,502 | -31% | -$15,484,143 | |||||
2025-12-16 | SRRK | Scholar Rock Holding Corp | Peng Katie | Dir | S - Sale | $44.09 | -1,006 | 32,908 | -3% | -$44,352 | ||||||
2025-12-17 | RGEN | Repligen Corp | Dawes Karen A | Dir | S - Sale | $161.00 | -275 | 91,821 | 0% | -$44,275 | ||||||
2025-12-16 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $76.82 | -2,688 | 47,884 | -5% | -$206,484 | ||||||
2025-12-16 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale | $76.82 | -15,394 | 937,367 | -2% | -$1,182,526 | ||||||
2025-12-16 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale | $76.82 | -5,447 | 278,600 | -2% | -$418,423 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |